We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreAmong the most expensive therapies are gene therapies that show promise to transform inherited disor...
Read moreThe Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...
Read moreThe provision of funding for Early Access Programmes is not ubiquitous. We explore which EU5 countri...
Read moreOur experts provide an overview of the five key trends that could shape the pricing and market acces...
Read moreOur experts reflect on the trends that shaped the European pricing and market access landscape in 20...
Read moreWe summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...
Read moreFrom 2016, the Innovation Fund has served as an instrument of central health policy to promote new f...
Read moreThis law is projected to have a large impact on the pharmaceutical industry and pharmacies nationwid...
Read moreWe analyse subscription-based agreements for antibiotics in Europe to understand how it may address ...
Read more